– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...

Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Swiss pharma giant Roche won approval from the ...

Credit: Getty Images. The SC formulation is intended to be administered in 10 minutes twice a year. Positive data were announced from a phase 3 trial evaluating an investigational subcutaneous (SC) ...

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...

Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA approval for Ocrevus Zunovo. Ocrevus Zunovo's ...

Please provide your email address to receive an email when new articles are posted on . The European Commission has authorized a subcutaneous injection of Ocrevus to treat relapsing multiple sclerosis ...

Ocrevus (ocrelizumab) is prescribed to treat certain forms of multiple sclerosis. The drug comes as a solution for intravenous (IV) infusion (into a vein). Ocrevus may not be safe to receive while ...